BR9814432A - Composições derivadas de mycobacterium vaccae e processo para seu uso - Google Patents

Composições derivadas de mycobacterium vaccae e processo para seu uso

Info

Publication number
BR9814432A
BR9814432A BR9814432-4A BR9814432A BR9814432A BR 9814432 A BR9814432 A BR 9814432A BR 9814432 A BR9814432 A BR 9814432A BR 9814432 A BR9814432 A BR 9814432A
Authority
BR
Brazil
Prior art keywords
vaccae
mycobacterium vaccae
compositions derived
derived
delipidized
Prior art date
Application number
BR9814432-4A
Other languages
English (en)
Inventor
Paul Tan
James Watson
Elizabeth S Visser
Margot A Skinner
Ross L Prestidge
Original Assignee
Genesis Res & Dev Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/997,362 external-priority patent/US5985287A/en
Priority claimed from US08/997,080 external-priority patent/US5968524A/en
Priority claimed from US09/095,855 external-priority patent/US6160093A/en
Priority claimed from US09/205,426 external-priority patent/US6406704B1/en
Application filed by Genesis Res & Dev Corp Ltd filed Critical Genesis Res & Dev Corp Ltd
Publication of BR9814432A publication Critical patent/BR9814432A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção:<B>"COMPOSIçõES DERIVADAS DE MYCOBACTERIUM VACCAE E PROCESSO PARA SEU USO"<D>. A presente invenção provê composições que estão presentes em ou podem ser derivadas de Mycobacterium vaccae, junto com processos para seu uso no tratamento, prevenção e detecção de distúrbios incluindo doenças infecciosas, distúrbios imunes e câncer. Os processos para melhorar a resposta imune a um antígeno incluindo administração de filtrado de cultura de M. vaccae, células de M. vaccae deslipidizado ou células de M. vaccae deslipidizado e desglicolipidizado são também providos.
BR9814432-4A 1997-12-23 1998-12-23 Composições derivadas de mycobacterium vaccae e processo para seu uso BR9814432A (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US99662497A 1997-12-23 1997-12-23
US08/997,362 US5985287A (en) 1996-08-29 1997-12-23 Compounds and methods for treatment and diagnosis of mycobacterial infections
US08/997,080 US5968524A (en) 1997-12-23 1997-12-23 Methods and compounds for the treatment of immunologically-mediated psoriasis
US09/095,855 US6160093A (en) 1996-08-29 1998-06-11 Compounds and methods for treatment and diagnosis of mycobacterial infections
US15618198A 1998-09-17 1998-09-17
US09/205,426 US6406704B1 (en) 1996-08-29 1998-12-04 Compounds and methods for treatment and diagnosis of mycobacterial infections
PCT/NZ1998/000189 WO1999032634A2 (en) 1997-12-23 1998-12-23 Compositions derived from mycobacterium vaccae and methods for their use

Publications (1)

Publication Number Publication Date
BR9814432A true BR9814432A (pt) 2000-10-10

Family

ID=27557521

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814432-4A BR9814432A (pt) 1997-12-23 1998-12-23 Composições derivadas de mycobacterium vaccae e processo para seu uso

Country Status (15)

Country Link
EP (1) EP1044273A2 (pt)
JP (1) JP2002514385A (pt)
CN (1) CN1294632A (pt)
AU (1) AU746311B2 (pt)
BR (1) BR9814432A (pt)
CA (1) CA2315539A1 (pt)
HU (1) HUP0100352A2 (pt)
ID (1) ID26327A (pt)
IL (1) IL136821A0 (pt)
MX (1) MXPA00006168A (pt)
NO (1) NO20003261L (pt)
NZ (1) NZ505834A (pt)
PL (1) PL341697A1 (pt)
TR (1) TR200001948T2 (pt)
WO (1) WO1999032634A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569436B1 (en) 1998-10-05 2003-05-27 The Malaghan Institute Of Medical Research Method of using a vaccine
JP4415200B2 (ja) * 1999-01-29 2010-02-17 大塚製薬株式会社 遅発育性抗酸菌ポリペプチド
GB9903539D0 (en) * 1999-02-16 1999-04-07 Stanford Rook Ltd Therapy using M.Vaccae
US6462669B1 (en) 1999-04-06 2002-10-08 E. P . Survivors Llc Replaceable LED modules
US6350457B1 (en) * 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
AU784847B2 (en) * 1999-07-12 2006-07-06 Genesis Research And Development Corporation Limited Compounds for treatment of infectious and immune system disorders and methods for their use
AU6820000A (en) * 1999-08-31 2001-03-26 Novozymes A/S Novel proteases and variants thereof
US7217554B2 (en) 1999-08-31 2007-05-15 Novozymes A/S Proteases and variants thereof
EP1208207A2 (de) * 1999-08-31 2002-05-29 Michael Niederweis Verfahren zur herstellung eines kanalbildenden proteins
US6361776B1 (en) * 1999-12-06 2002-03-26 Genesis Research & Development Corp. Ltd. Compounds isolated from M. vaccae and their use in modulation of immune responses
AU2403901A (en) * 1999-12-28 2001-07-09 Ichiro Azuma Maturation-promoting agent for immature dendritic cells
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
WO2002094184A2 (en) * 2001-05-11 2002-11-28 Corixa Corporation Vaccines for the treatment of autoimmune disease
US20030147861A1 (en) * 2001-07-26 2003-08-07 Genesis Research And Development Corporation Limited Compounds and methods for the modulation of immune responses
WO2003049751A1 (en) * 2001-12-10 2003-06-19 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
GB0303507D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
RU2695462C2 (ru) * 2014-01-09 2019-07-23 Трансген Са Гибридизация гетероолигомерных микобактериальных антигенов
CN116139254B (zh) * 2021-08-10 2025-04-22 昆明医科大学 一种具有提高免疫力和抗肿瘤以及延长寿命的多肽及其应用
CN119162167B (zh) * 2024-11-21 2025-03-11 四川大学华西医院 一种分枝杆菌基因组的提取方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections

Also Published As

Publication number Publication date
HUP0100352A2 (hu) 2001-06-28
IL136821A0 (en) 2001-06-14
TR200001948T2 (tr) 2001-02-21
MXPA00006168A (es) 2005-02-24
ID26327A (id) 2000-12-14
CA2315539A1 (en) 1999-07-01
PL341697A1 (en) 2001-04-23
EP1044273A2 (en) 2000-10-18
WO1999032634A3 (en) 1999-12-02
CN1294632A (zh) 2001-05-09
NO20003261D0 (no) 2000-06-22
AU1893699A (en) 1999-07-12
NZ505834A (en) 2002-12-20
NO20003261L (no) 2000-08-22
AU746311B2 (en) 2002-04-18
WO1999032634A2 (en) 1999-07-01
JP2002514385A (ja) 2002-05-21

Similar Documents

Publication Publication Date Title
BR9814432A (pt) Composições derivadas de mycobacterium vaccae e processo para seu uso
DE60038104D1 (de) Arzneimittelzubereitungen für die behandlung von alpha-galactosidase a-mangel
BR9711457A (pt) Compostos e processo para o tratamento e diagnóstico de infecções micobacterianas.
ES2150496T3 (es) Cicloalquilimidazopiridinas condensadas.
PT726758E (pt) Peptidos para induzir respostas de linfocitos t citotoxicos ao virus da hepatite b
BG101103A (bg) Теломераза при бозайници
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
ATE517125T1 (de) ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN
IL192679A0 (en) Aglyco products and uses thereof
SE8703225L (sv) Monoklonala antikroppar och peptider anvendbara vid behandling och diagnostisering av hiv-infektioner
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
ATE179614T1 (de) Herpes simplex virus vp16 impfstoffe
GB2355983A (en) Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class 1 molecule and an attaching means
YU166790A (sh) Kompleksi koji imaju pomoćnu aktivnost
BR0109164A (pt) Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos
NO920331D0 (no) Biologisk preparat samt bruk derav
DE59002154D1 (de) Kombinationspraeparate enthaltend rifampicin und thioacetazon sowie gegebenenfalls isonicotinsaeurehydrazid oder ethambutol als aktive wirkstoffe.
BR9612422A (pt) Pseudo-partìculas virais recombinantes, composição, utilização de pseudo-partìculas, e, processo de estimulação in vitro de respostas t citotóxicas de linfócitos provenientes de indivìduos atingidos por infecções virais ou tumorais.
BR9910594A (pt) Vìrus de herpes simplex, uso de um vìrus de herpessimplex, composição farmacêutica e processospara estudar a função de um gene heterólogo emuma célula de mamìfero, para produzir um vìrus deherpes simplex e para tratar um distúrbio ou uma lesãodo sistema nervoso de um mamìfero
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
DE69927794D1 (de) Zusammensetzungen zum nachweis und zur diagnose von infektiösen mykobakteriellen krankheiten
BR9307176A (pt) Métodos para identificação de um paciente contaminado com hiv para determinar a eficácia do tratamento de um paciente humano infectado com hiv e processo para identificar os indivíduos contaminados com hiv
Fitzgerald et al. Role of interferon in natural kill of herpesvirus infected fibroblasts
AU2396900A (en) Treatment and prevention of hiv and other viral infections
Cesbron et al. Homozygous C 5 deficiency revealed by Neisseria meningitidis meningitis.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1890 DE 27/03/2007.